YARDLEY, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and
throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter and
year-end 2017, before market open on Tuesday, March 13, 2018.
Members of the Company’s leadership team will host a conference call to discuss financial results and corporate
updates, including the expected retail availability of XHANCETM in early April 2018, beginning at 8:00 a.m. Eastern Time on
Tuesday, March 13, 2018.
To participate on the conference call, please dial (866) 916-4761 from the U.S. or (409) 216-6496 from outside
the U.S. In addition, following the completion of the call, a telephone replay will be accessible until March 20, 2018 by dialing
(855) 859-2056 from the U.S. or (404) 537-3406 from outside the U.S. and entering conference ID # 9246888. A simultaneous webcast
of the call and presentation can be accessed by visiting the Investor section of Optinose’s website at www.optinose.com. In addition, a replay of the webcast will be available on the Company website
for 60 days following the event.
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat
(ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
purpose and include, among others, statements relating to: the planned retail availability of XHANCE in early April 2018 and other
future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a
number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from
those indicated by such forward-looking statements including, among others: our ability to establish supply chain and commercial
infrastructure and capabilities to launch XHANCE; physician and patient acceptance of XHANCE; our ability to obtain adequate
third-party reimbursement for XHANCE; varying interpretation of clinical data; and the risks, uncertainties and other factors
discussed in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission – which are
available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any
forward-looking statements made in this press release speak only as of the date of this press release, and we undertake no
obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.
Optinose Investor Contact
Jonathan Neely
Jonathan.neely@optinose.com
267.521.0531
